EPISODE · Jun 2, 2025 · 11 MIN
ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer
from BiotechTV - News · host BiotechTV
He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared to one product that is already on the market.
Embed this episode
Ready to play
ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer
0:00
11:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 11 minutes long.
When was this BiotechTV - News episode published?
This episode was published on June 2, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!